Clinical Trial Update: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) [Phase 3]

View source ↗

Summary

This clinical trial update describes the Phase 3 LUCENT 3 study evaluating the long-term efficacy and safety of mirikizumab in participants with moderately to s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ulcerative Colitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING